CN104887844A - Medicinal composition for resisting atherosclerosis and application thereof - Google Patents
Medicinal composition for resisting atherosclerosis and application thereof Download PDFInfo
- Publication number
- CN104887844A CN104887844A CN201510281712.XA CN201510281712A CN104887844A CN 104887844 A CN104887844 A CN 104887844A CN 201510281712 A CN201510281712 A CN 201510281712A CN 104887844 A CN104887844 A CN 104887844A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- crude drug
- antiatherogenic
- medicinal composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicinal composition for resisting atherosclerosis and application thereof. The medicinal composition is prepared from the following traditional Chinese medicinal materials in parts by mass by virtue of water decoction and extraction: 10-18 parts of mulberry leaf, 20-33 parts of common goldenrod herb, 16-23 parts of balsam pear leaf, 30-39 parts of flower of Japanese pagoda tree, 10-18 parts of simple-leaf shrub chastetree fruit, 3-7 parts of costustoot, 10-18 parts of seaweed, 10-18 parts of biond magnolia flower bud, 16-23 parts of common selfheal fruit-spike and 20-33 parts of black fungus. The medicinal composition can give play to a relatively ideal effect of resisting atherosclerosis by adjusting blood fat and reducing damages of lipids to endothelial cells.
Description
Technical field
The invention belongs to technical field of Chinese medicine, in particular to the antiatherogenic pharmaceutical composition of one and application thereof.
Background technology
Atherosclerosis be a kind of by multifactor facilitate change into main chronic, progressive disease with large, medium-sized artery chronic inflammatory disease, be characterized in vascellum tunica interna incrassation, lipidosis, and can atherosclerotic stenosis be caused, systemic arterial blood vessel can be involved, especially common with coronary artery and cervical region, entocranial artery.Richard etc. show through massive epidemiology investigation and experimentation, hyperlipidemia, smoking, diabetes, hypertension, sex difference etc. are all that relevant risk factor occurs with atherosclerosis, and hyperlipemia is atherogenic immediate cause and primary risk factor, Hyperlipemia is one of the most dangerous (easily suffering from) factor accelerated in the multiple factor of atherosclerosis.Wherein serum cholesterol level and to be atheroscleroticly proportionate.Therefore, restriction cholesterol absorption, high density lipoprotein increasing (HDL), inhibited oxidation stress level and arterial wall inflammation have become the atherosclerotic important means of control.
Research prophylactico-therapeutic measures and the effective medicine of searching are the research fields that the whole world is very paid attention to, and western scholar tends to the research in Western medicine, operation and gene, and Western medicine has side effect in various degree mostly.As can be seen here, the little Antiatherosclerosis medicine of a kind of toxic and side effects is needed to seem particularly important.Chinese medicine has the advantage of uniqueness in hyperlipemia and cardiovascular and cerebrovascular disease preventing and treating, its curative effect certainly, lasting, side effect is little.China due to combination of Chinese and Western medicine work fruitful, non-operative treatment occupies greater advantage, and Chinese medicine becomes first-selected therapy approach.
Summary of the invention
In view of Chinese medicine is preventing and treating the advantage having uniqueness in hyperlipemia and cardiovascular and cerebrovascular disease, the object of the invention is to further investigate folk remedy and optimize, thus a kind of antiatherogenic pharmaceutical composition and application thereof are provided, the blood lipid level of this pharmaceutical composition functions for the treatment of hyperlipidemia disease patient, suppresses the formation of atheromatous plaque.
In order to realize object of the present invention, inventor is studied by lot of experiments, finally obtains following technical scheme:
A kind of antiatherogenic pharmaceutical composition, is prepared from through water boiling and extraction by the Chinese crude drug of following mass parts: Folium Mori 10-18 part, Herba Solidaginis 20-33 part, Folium Momordicae Charantiae 16-23 part, Flos Sophorae 30-39 part, Fructus Viticis 10-18 part, Radix Aucklandiae 3-7 part, Sargassum 10-18 part, Flos Magnoliae 10-18 part, Spica Prunellae 16-23 part, Auricularia 20-33 part.
Preferably, described antiatherogenic pharmaceutical composition, is prepared from through water boiling and extraction by the Chinese crude drug of following mass parts: Folium Mori 12-15 part, Herba Solidaginis 24-28 part, Folium Momordicae Charantiae 18-20 part, Flos Sophorae 33-36 part, Fructus Viticis 12-15 part, Radix Aucklandiae 4-6 part, Sargassum 12-15 part, Flos Magnoliae 12-15 part, Spica Prunellae 18-20 part, Auricularia 24-28 part.
Further preferably, described antiatherogenic pharmaceutical composition, is prepared from through water boiling and extraction by the Chinese crude drug of following mass parts: 13 parts, Folium Mori, Herba Solidaginis 26 parts, Folium Momordicae Charantiae 19 parts, 35 parts, Flos Sophorae, Fructus Viticis 13 parts, the Radix Aucklandiae 5 parts, Sargassum 13 parts, Flos Magnoliae 13 parts, Spica Prunellae 19 parts, Auricularia 26 parts.
Any one antiatherogenic pharmaceutical composition above-mentioned, it is made into oral formulations, comprises oral liquid, tablet, capsule and granule.These oral formulations all can on the basis of Chinese medicine extract, add adjuvant available on pharmaceutics, as included but are not limited to filler (diluent), disintegrating agent, lubricant (fluidizer), binding agent, solubilizing agent, antioxidant, emulsifying agent etc., be prepared from by the conventional formulation technique of this area.
It should be noted that, traditional Chinese medicinal material raw materials source of the present invention is as follows: Folium Mori select the dried leaves of moraceae plants Mulberry Morus alba L..Herba Solidaginis selects the dry root of feverfew Herba Solidaginis platymiscium Herba Solidaginis Solidago decurrens Lour..Folium Momordicae Charantiae selects the dried leaves of Cucurbitaceae Momordica plant Fructus Momordicae charantiae Momordica charantia L..Flos Sophorae selects the dry flower of leguminous plant Chinese scholartree Sophora japonica L..Fructus Viticis selects the dry mature fruit of Verbenaceae wild pepper Vitex trifoliaL..The Radix Aucklandiae selects the dry root of feverfew Radix Aucklandiae Aucklandia lappa Decne..Sargassum selects the dry frond of Sargassaceae plant Sargassum Sargassum pallidum (Turn.) C.Ag..Flos Magnoliae selects the dry flower of Magnoliacea plant Flos Magnoliae Magnolia biondii Pamp..Spica Prunellae selects the dry fruit ear of labiate Spica Prunellae Prunella vulgaris L..The dry sporophore of Auriculariaceae Auricularia plant Auricularia Auricularia auricula (L.) Underw. selected by Auricularia.
Results of animal shows, pharmaceutical composition scalable blood fat of the present invention, reduces TC and LDL-C, reduces endarterium lipid and is formed, have obvious blood fat reducing, study of anti-atherogenic effect.The function of endotheliocyte, morphologic change or damage are the initiating links that atherosclerosis occurs, the inside and outside experiment of many bodies confirms, during endothelial injury, endotheliocyte can discharge some somatomedin, causes complicated biological effect, finally causes arterial wall smooth muscle cell to be bred.In tube wall, excessive lipid is not easily eliminated, and is engulfed by smooth muscle cell, mononuclear cell, forms foam cell.Experimentation shows: the rat model through medicine composite for curing of the present invention presents a small amount of lipidosis, therefore has certain study of anti-atherogenic effect.Experiment light microscopic, electron microscopy study result are consistent with above-mentioned research: model group endothelial cell damage, speckle fills the air, speckle is thicker, and area is large.Thus cause atheromatous plaque to be formed.And pharmaceutical composition group endotheliocyte partial exfoliation of the present invention, form, structure are more complete, and speckle compares limitation, and speckle is thin, and area is little.Go up results presumption according to this: pharmaceutical composition of the present invention, by adjusting blood lipid, reduces the damage of lipid Human Umbilical Vein Endothelial Cells, thus plays ideal study of anti-atherogenic effect.
Detailed description of the invention
Be below specific embodiments of the invention, technical scheme of the present invention is done to describing further, but protection scope of the present invention be not limited to these embodiments.Every do not deviate from the present invention's design change or equivalent substituting include within protection scope of the present invention.
Embodiment 1: the preparation of Chinese medicine extract
Crude drug prescription: Folium Mori 130g, Herba Solidaginis 260g, Folium Momordicae Charantiae 190g, Flos Sophorae 350g, Fructus Viticis 130g, Radix Aucklandiae 50g, Sargassum 130g, Flos Magnoliae 130g, Spica Prunellae 190g, Auricularia 260g.
Preparation technology: the above-mentioned Chinese crude drug taking recipe quantity, merges, and pulverizes, add water and cover powder 2cm, soak 1-1.2h, pull medical material out and put in multi-function extractor and decoct with water 2 times, add up the purified water of medical material 12 times amount for 1st time, decoct 3h, get decocting liquid, filter, add up the purified water of medical material 10 times amount for 2nd time, decoct 2h, get twice decocting liquid and merge, filter, be concentrated into every milliliter containing 1.0g crude drug amount, stir, put 5 DEG C of deepfreeze 24h, cold preservation liquid is filtered, heating is concentrated into thick paste, dry, pulverize, obtain Chinese medicine extract dried cream powder.
Embodiment 2: the preparation of Chinese medicine oral liquid
Crude drug prescription: Folium Mori 130g, Herba Solidaginis 260g, Folium Momordicae Charantiae 190g, Flos Sophorae 350g, Fructus Viticis 130g, Radix Aucklandiae 50g, Sargassum 130g, Flos Magnoliae 130g, Spica Prunellae 190g, Auricularia 260g.
Preparation technology: the above-mentioned Chinese crude drug taking recipe quantity, merges, and pulverizes, adds water and cover powder 2cm, soak 1-1.2h, pull medical material out and put during multi-functional extractions is filled with and decoct with water 2 times, the purified water of the 1st totalling medical material 12 times amount, decoct 3h, get decocting liquid, filter, add up the purified water of medical material 10 times amount for 2nd time, decoct 2h, get twice decocting liquid and merge, filter, be concentrated into every milliliter containing 2.5g crude drug amount, stir, put 5 DEG C of deepfreeze 24h, cold preservation liquid is filtered, obtains oral liquid.
Embodiment 3: the preparation of Chinese medicine oral liquid
Crude drug prescription: Folium Mori 150g, Herba Solidaginis 300g, Folium Momordicae Charantiae 180g, Flos Sophorae 390g, Fructus Viticis 180g, Radix Aucklandiae 50g, Sargassum 180g, Flos Magnoliae 130g, Spica Prunellae 200g, Auricularia 330g.
Preparation technology: the above-mentioned Chinese crude drug taking recipe quantity, merges, and pulverizes, adds water and cover powder 2cm, soak 1-1.2h, pull medical material out and put during multi-functional extractions is filled with and decoct with water 2 times, the purified water of the 1st totalling medical material 12 times amount, decoct 3h, get decocting liquid, filter, add up the purified water of medical material 10 times amount for 2nd time, decoct 2h, get twice decocting liquid and merge, filter, be concentrated into every milliliter containing 2.3g crude drug amount, stir, put 5 DEG C of deepfreeze 24h, cold preservation liquid is filtered, obtains oral liquid.
Embodiment 4: Chinese medicine extract is to the effectiveness study of atherosclerotic rat
Healthy Male Wistar Rats 40, weight 240-260g, after feeding 7d with normal feedstuff adaptability, weigh, more than fasting 8h, is divided into following four groups: normal group at random, model group and extract high and low dose group.Often organize rat 10.Normal group continues to give normal diet, and other three groups give high lipid food (cholesterol 3%, sodium cholate 0.5%, propylthiouracil 0.2%, white sugar 5%, Adeps Sus domestica 10%, normal diet 81.3%).Continuous nursing 1 month, simultaneously disposable celiac injection vitamin D 600,000 IU/kg when feeding starts, the normal saline of normal group lumbar injection equal volume.Extract high and low dose group modeling simultaneously respectively with embodiment 1 prepare Chinese medicine extract dried cream powder 73.6mg/ (kgd), 36.8mg/ (kgd), every day 1 gavage; Normal group and model group are with normal saline gavage.The each treated animal of experimental session is freely ingested, is drunk water.After administration 30d, carotid artery gets blood, detects serum three ester glycerol (TG), T-CHOL (TC), HDL-C (HDL-C).After the blood sampling of each group of rat terminates, quick clip aortic arch, vertical profile is cut into long 8-10mm piece of tissue, and speed drops in 10% formalin solution fixing, and dehydration, transparent, embedding, section, conventional H E dyes, and puts optical microphotograph Microscopic observation, takes pictures.Electron microscope specimen makes: first fix with 2.5% glutaraldehyde, 0.1MPBS rinsing, fixing after 1% hungry acid, acetone dewaters step by step, and 50% → 70% → 90% → 100%, totally 4 times, Epon812 epoxy resin buries entirely, and treating block machine repaiies block, and ultramicrotome is cut into slices, acetic acid uranium, plumbi nitras double staining, transmission electron microscope observing.Result of the test is added up and is analyzed as follows:
(1) can be found out by the result of the test of table 1, after rat causes Atherosclerosis Model, serum TC, TG compared with normal group obviously raise (P < 0.01), and Serum HDL-C is then without significant change (P > 0.05).The each dosage group of Chinese medicine extract all can reduce hyperlipidemia rats TG, TC level (P < 0.01 or P < 0.05), raise HDL-C level (P < 0.01 or P < 0.05), this illustrates pharmaceutical composition energy adjusting blood lipid of the present invention, has potential therapeutic potential to atherosclerosis.
Table 1 Chinese medicine extract is on the impact (mmol/L, n=10) of atherosclerotic rat blood fat
| Group | TG | TC | HDL-C |
| Normal group | 1.09±0.06 | 2.05±1.29 | 0.70±0.20 |
| Model group | 1.71±0.10 ★★ | 6.42±1.15 ★★ | 0.63±0.17 |
| Extract high dose group | 1.43±0.09 ▲▲ | 3.33±1.10 ▲▲ | 1.07±0.44 ▲ |
| Extract low dose group | 1.56±0.07 ▲ | 3.75±1.62 ▲ | 1.13±0.26 ▲▲ |
Model group compares with normal group,
★p < 0.05,
★ ★p < 0.01; Extract group compares with model group,
▲p < 0.05,
▲ ▲p < 0.01.
(2) blood vessel wall lipid HE coloration result display: normal group animal aorta does not find pathological changes.Model group speckle fills the air, speckle is thicker, and area is large.Chinese medicine extract group speckle compares limitation, and speckle is thin, and area is little.Image analysis showed, model group plaque area accounts for gross area percentage ratio and is obviously greater than normal group, and Chinese medicine extract treatment group all significantly reduces plaque area.Electron microscope showed: normal group nucleus ovalize, chromatin fraction coagulation, nuclear membrane is complete, and Cell tracking is tightr.Model group nucleus differs in size, and nucleus has split coil method, and core is irregular, and after birth caves in, and structure of mitochondria is unclear, and Distribution of chromatin is uneven, in block coagulation.The karyomorphism of Chinese medicine extract high and low dose group is irregular, and cell connects comparatively tight, and nuclear membrane is more complete, and the distribution of nuclei dyeing chromaticness is relatively more even, and part nuclei dyeing chromaticness has agglutination phenomenon, and part endochylema skewness, organelle structure is unclear.
Claims (6)
1. an antiatherogenic pharmaceutical composition, is characterized in that described pharmaceutical composition is prepared from through water boiling and extraction by the Chinese crude drug of following mass parts: Folium Mori 10-18 part, Herba Solidaginis 20-33 part, Folium Momordicae Charantiae 16-23 part, Flos Sophorae 30-39 part, Fructus Viticis 10-18 part, Radix Aucklandiae 3-7 part, Sargassum 10-18 part, Flos Magnoliae 10-18 part, Spica Prunellae 16-23 part, Auricularia 20-33 part.
2. antiatherogenic pharmaceutical composition according to claim 1, is characterized in that described pharmaceutical composition is prepared from through water boiling and extraction by the Chinese crude drug of following mass parts: Folium Mori 12-15 part, Herba Solidaginis 24-28 part, Folium Momordicae Charantiae 18-20 part, Flos Sophorae 33-36 part, Fructus Viticis 12-15 part, Radix Aucklandiae 4-6 part, Sargassum 12-15 part, Flos Magnoliae 12-15 part, Spica Prunellae 18-20 part, Auricularia 24-28 part.
3. antiatherogenic pharmaceutical composition according to claim 2, is characterized in that described pharmaceutical composition is prepared from through water boiling and extraction by the Chinese crude drug of following mass parts: 13 parts, Folium Mori, Herba Solidaginis 26 parts, Folium Momordicae Charantiae 19 parts, 35 parts, Flos Sophorae, Fructus Viticis 13 parts, the Radix Aucklandiae 5 parts, Sargassum 13 parts, Flos Magnoliae 13 parts, Spica Prunellae 19 parts, Auricularia 26 parts.
4., according to the arbitrary described antiatherogenic pharmaceutical composition of claim 1-3, it is characterized in that: described pharmaceutical composition is made into oral formulations, comprise oral liquid, tablet, capsule and granule.
5. according to the application of the arbitrary described Chinese crude drug compositions of claim 1-3 in the medicine of preparation blood fat reducing.
6. according to the application of the arbitrary described Chinese crude drug compositions of claim 1-3 in the antiatherogenic medicine of preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510281712.XA CN104887844A (en) | 2015-05-28 | 2015-05-28 | Medicinal composition for resisting atherosclerosis and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510281712.XA CN104887844A (en) | 2015-05-28 | 2015-05-28 | Medicinal composition for resisting atherosclerosis and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104887844A true CN104887844A (en) | 2015-09-09 |
Family
ID=54021086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510281712.XA Pending CN104887844A (en) | 2015-05-28 | 2015-05-28 | Medicinal composition for resisting atherosclerosis and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104887844A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1836694A (en) * | 2005-03-25 | 2006-09-27 | 重庆大易科技投资有限公司 | Medicine composition for treating cardiovascular diseases and preparation method thereof |
| CN1911288A (en) * | 2006-08-18 | 2007-02-14 | 南京中医药大学 | Compounding traditional Chinese medicine-Xueyaping for treating primary hypertension, and its prepn. method |
-
2015
- 2015-05-28 CN CN201510281712.XA patent/CN104887844A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1836694A (en) * | 2005-03-25 | 2006-09-27 | 重庆大易科技投资有限公司 | Medicine composition for treating cardiovascular diseases and preparation method thereof |
| CN1911288A (en) * | 2006-08-18 | 2007-02-14 | 南京中医药大学 | Compounding traditional Chinese medicine-Xueyaping for treating primary hypertension, and its prepn. method |
Non-Patent Citations (2)
| Title |
|---|
| 王阶主编: "《实用中西医结合心血管病学》", 31 March 2007, 中国医药科技出版社 * |
| 田俊等: "降脂通脉方抗大鼠动脉粥样硬化的实验研究", 《中国中医急症》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106176918A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Radix Puerariae | |
| CN108524814A (en) | A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose | |
| CN1706463A (en) | Medicine for treating women's habitual abortion and threatened abortion | |
| CN106177053A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Pericarpium Citri Reticulatae | |
| CN106177183A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, green tea and Folium Mori | |
| CN101897925B (en) | Medicinal composition for treating metabolic syndrome | |
| CN103239624B (en) | Chinese medicine for treating oligospermia and asthenozoospermia owning to insufficiency of both spleen and kidney | |
| CN1478508A (en) | Chinese medicinal composition for treating fatty liver and its preparation method | |
| CN104042684B (en) | A kind of Chinese medicine composition containing Herb Gynostemmae Pentaphylli extract and preparation method | |
| JP7340113B2 (en) | Chinese herbal composition and its production method and use | |
| CN105327115B (en) | A kind of prevention and treatment type II diabetes Phellinus is logical to rush down formula and preparation process | |
| CN104887844A (en) | Medicinal composition for resisting atherosclerosis and application thereof | |
| CN106072099A (en) | A kind of health food of auxiliary reducing blood lipid containing green plum and preparation method thereof | |
| CN102599501B (en) | Healthcare Hongyang capsule or tablet product for lowering lipid and protecting liver | |
| CN106491922B (en) | Traditional Chinese medicine formula medicine suitable for qi stagnation and turbid phlegm type hyperlipemia and capsule thereof | |
| CN110840996A (en) | Traditional Chinese medicine formula, method, preparation and application for treating qi-yin deficiency metabolic syndrome | |
| CN101480434A (en) | Compound recipe for reducing blood fat as well as preparation method and application | |
| CN101112432A (en) | Fatty liver treating Chinese medicine and method for preparing the same | |
| CN108497494A (en) | A kind of health food and preparation method thereof of auxiliary reducing blood lipid | |
| CN103223143B (en) | Traditional Chinese medicine composition for treating simple obesity, and preparation method and application thereof | |
| CN108743885A (en) | A kind of Chinese medicine and preparation method thereof for treating Diabetic Macrovascular Complications | |
| CN107455742A (en) | A kind of preparation method with auxiliary lipid-lowering function product | |
| CN103285110B (en) | Traditional Chinese medicine for treating hyperlipidemia and preparation method thereof | |
| CN114712458B (en) | Pharmaceutical composition for treating vascular aging of hypertension and preparation method and application thereof | |
| CN106177578A (en) | A kind of Chinese medicine composition of blood fat reducing and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination |